Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Review Article

Non-Steroidal Androgen Receptor Antagonists and Prostate Cancer: A Survey on Chemical Structures Binding this Fast-Mutating Target

Author(s): Claudia Ferroni* and Greta Varchi*

Volume 26, Issue 33, 2019

Page: [6053 - 6073] Pages: 21

DOI: 10.2174/0929867325666180913095239

Price: $65

Abstract

The Androgen Receptor (AR) pathway plays a major role in both the pathogenesis and progression of prostate cancer. In particular, AR is chiefly involved in the development of Castration-Resistant Prostate Cancer (CRPC) as well as in the resistance to the secondgeneration AR antagonist enzalutamide, and to the selective inhibitor of cytochrome P450 17A1 (CYP17A1) abiraterone. Several small molecules acting as AR antagonists have been designed and developed so far, also as a result of the ability of cells expressing this molecular target to rapidly develop resistance and turn pure receptor antagonists into ineffective or event detrimental molecules. This review covers a survey of most promising classes of non-steroidal androgen receptor antagonists, also providing insights into their mechanism of action and efficacy in treating prostate cancer.

Keywords: Androgen receptor, castration resistant prostate cancer, antiandrogens, point mutations, PROTACs, AR protein degraders, AR-targeting conjugates.

[1]
Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer Statistics, 2017. CA Cancer J. Clin., 2017, 67(1), 7-30.
[http://dx.doi.org/10.3322/caac.21387] [PMID: 28055103]
[2]
Buttigliero, C.; Tucci, M.; Bertaglia, V.; Vignani, F.; Bironzo, P.; Di Maio, M.; Scagliotti, G.V. Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer. Cancer Treat. Rev., 2015, 41(10), 884-892.
[http://dx.doi.org/10.1016/j.ctrv.2015.08.002] [PMID: 26342718]
[3]
Galletti, G.; Leach, B.I.; Lam, L.; Tagawa, S.T. Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer. Cancer Treat. Rev., 2017, 57, 16-27.
[http://dx.doi.org/10.1016/j.ctrv.2017.04.008] [PMID: 28527407]
[4]
Waltering, K.K.; Urbanucci, A.; Visakorpi, T. Androgen receptor (AR) aberrations in castration-resistant prostate cancer. Mol. Cell. Endocrinol., 2012, 360(1-2), 38-43.
[http://dx.doi.org/10.1016/j.mce.2011.12.019] [PMID: 22245783]
[5]
Jenster, G.; van der Korput, H.A.; van Vroonhoven, C.; van der Kwast, T.H.; Trapman, J.; Brinkmann, A.O. Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. Mol. Endocrinol., 1991, 5(10), 1396-1404.
[http://dx.doi.org/10.1210/mend-5-10-1396] [PMID: 1775129]
[6]
Mohler, J.L.; Gregory, C.W.; Ford, O.H., III; Kim, D.; Weaver, C.M.; Petrusz, P.; Wilson, E.M.; French, F.S. The androgen axis in recurrent prostate cancer. Clin. Cancer Res., 2004, 10(2), 440-448.
[http://dx.doi.org/10.1158/1078-0432.CCR-1146-03] [PMID: 14760063]
[7]
Parimi, V.; Goyal, R.; Poropatich, K.; Yang, X.J. Neuroendocrine differentiation of prostate cancer: a review. Am. J. Clin. Exp. Urol., 2014, 2(4), 273-285.
[PMID: 25606573]
[8]
Martinez-Ariza, G.; Hulme, C. Recent advances in allosteric androgen receptor inhibitors for the potential treatment of castration-resistant prostate cancer. Pharm. Pat. Anal., 2015, 4(5), 387-402.
[http://dx.doi.org/10.4155/ppa.15.20] [PMID: 26389532]
[9]
Linja, M.J.; Savinainen, K.J.; Saramäki, O.R.; Tammela, T.L.; Vessella, R.L.; Visakorpi, T. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res., 2001, 61(9), 3550-3555.
[PMID: 11325816]
[10]
Lallous, N.; Volik, S.V.; Awrey, S.; Leblanc, E.; Tse, R.; Murillo, J.; Singh, K.; Azad, A.A.; Wyatt, A.W.; LeBihan, S.; Chi, K.N.; Gleave, M.E.; Rennie, P.S.; Collins, C.C.; Cherkasov, A. Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients. Genome Biol., 2016, 17(1), 10.
[http://dx.doi.org/10.1186/s13059-015-0864-1] [PMID: 26813233]
[11]
Antonarakis, E.S.; Chandhasin, C.; Osbourne, E.; Luo, J.; Sadar, M.D.; Perabo, F. Targeting the N-terminal domain of the androgen receptor: A new approach for the treatment of advanced prostate cancer. Oncologist, 2016, 21(12), 1427-1435.
[http://dx.doi.org/10.1634/theoncologist.2016-0161] [PMID: 27628492]
[12]
Sprenger, C.C.T.; Plymate, S.R. The link between androgen receptor splice variants and castration-resistant prostate cancer. Horm. Cancer, 2014, 5(4), 207-217.
[http://dx.doi.org/10.1007/s12672-014-0177-y] [PMID: 24798453]
[13]
Kumagai, J.; Hofland, J.; Erkens-Schulze, S.; Dits, N.F.J.; Steenbergen, J.; Jenster, G.; Homma, Y.; de Jong, F.H.; van Weerden, W.M. Intratumoral conversion of adrenal androgen precursors drives androgen receptor-activated cell growth in prostate cancer more potently than de novo steroidogenesis. Prostate, 2013, 73(15), 1636-1650.
[http://dx.doi.org/10.1002/pros.22655] [PMID: 23996639]
[14]
Cai, C.; Balk, S.P. Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy. Endocr. Relat. Cancer, 2011, 18(5), R175-R182.
[http://dx.doi.org/10.1530/ERC-10-0339] [PMID: 21712345]
[15]
Li, Y.; Chan, S.C.; Brand, L.J.; Hwang, T.H.; Silverstein, K.A.T.; Dehm, S.M. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res., 2013, 73(2), 483-489.
[http://dx.doi.org/10.1158/0008-5472.CAN-12-3630] [PMID: 23117885]
[16]
Mostaghel, E.A.; Marck, B.T.; Plymate, S.R.; Vessella, R.L.; Balk, S.; Matsumoto, A.M.; Nelson, P.S.; Montgomery, R.B. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin. Cancer Res., 2011, 17(18), 5913-5925.
[http://dx.doi.org/10.1158/1078-0432.CCR-11-0728] [PMID: 21807635]
[17]
Watson, P.A.; Arora, V.K.; Sawyers, C.L. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat. Rev. Cancer, 2015, 15(12), 701-711.
[http://dx.doi.org/10.1038/nrc4016] [PMID: 26563462]
[18]
Momtazi-Borojeni, A.A.; Abdollahi, E.; Ghasemi, F.; Caraglia, M.; Sahebkar, A. The novel role of pyrvinium in cancer therapy. J. Cell. Physiol., 2018, 233(4), 2871-2881.
[http://dx.doi.org/10.1002/jcp.26006] [PMID: 28500633]
[19]
Tan, M.H.; Li, J.; Xu, H.E.; Melcher, K.; Yong, E-L. Androgen receptor: structure, role in prostate cancer and drug discovery. Acta Pharmacol. Sin., 2015, 36(1), 3-23.
[http://dx.doi.org/10.1038/aps.2014.18] [PMID: 24909511]
[20]
Myung, J-K.; Banuelos, C.A.; Fernandez, J.G.; Mawji, N.R.; Wang, J.; Tien, A.H.; Yang, Y.C.; Tavakoli, I.; Haile, S.; Watt, K.; McEwan, I.J.; Plymate, S.; Andersen, R.J.; Sadar, M.D. An androgen receptor N-terminal domain antagonist for treating prostate cancer. J. Clin. Invest., 2013, 123(7), 2948-2960.
[http://dx.doi.org/10.1172/JCI66398] [PMID: 23722902]
[21]
Cattrini, C.; Zanardi, E.; Vallome, G.; Cavo, A.; Cerbone, L.; Di Meglio, A.; Fabbroni, C.; Latocca, M.M.; Rizzo, F.; Messina, C.; Rubagotti, A.; Barboro, P.; Boccardo, F. Targeting androgen-independent pathways: new chances for patients with prostate cancer? Crit. Rev. Oncol. Hematol., 2017, 118, 42-53.
[http://dx.doi.org/10.1016/j.critrevonc.2017.08.009] [PMID: 28917268]
[22]
Tilki, D.; Schaeffer, E.M.; Evans, C.P. Understanding mechanisms of resistance in metastatic castration-resistant prostate cancer: the role of the androgen receptor. Eur. Urol. Focus, 2016, 2(5), 499-505.
[http://dx.doi.org/10.1016/j.euf.2016.11.013] [PMID: 28723515]
[23]
Hoang, D.T.; Iczkowski, K.A.; Kilari, D.; See, W.; Nevalainen, M.T. Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles. Oncotarget, 2017, 8(2), 3724-3745.
[http://dx.doi.org/10.18632/oncotarget.12554] [PMID: 27741508]
[24]
Liu, H-L.; Zhong, H-Y.; Song, T-Q.; Li, J-Z. A Molecular modeling study of the hydroxyflutamide resistance mechanism induced by androgen receptor mutations. Int. J. Mol. Sci., 2017, 18(9), 1823.
[http://dx.doi.org/10.3390/ijms18091823] [PMID: 28832499]
[25]
Krishnan, A.V.; Zhao, X-Y.; Swami, S.; Brive, L.; Peehl, D.M.; Ely, K.R.; Feldman, D. A glucocorticoid-responsive mutant androgen receptor exhibits unique ligand specificity: therapeutic implications for androgen-independent prostate cancer. Endocrinology, 2002, 143(5), 1889-1900.
[http://dx.doi.org/10.1210/endo.143.5.8778] [PMID: 11956172]
[26]
Zhao, X.Y.; Malloy, P.J.; Krishnan, A.V.; Swami, S.; Navone, N.M.; Peehl, D.M.; Feldman, D. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat. Med., 2000, 6(6), 703-706.
[http://dx.doi.org/10.1038/76287] [PMID: 10835690]
[27]
Guerrini, A.; Tesei, A.; Ferroni, C.; Paganelli, G.; Zamagni, A.; Carloni, S.; Di Donato, M.; Castoria, G.; Leonetti, C.; Porru, M.; De Cesare, M.; Zaffaroni, N.; Beretta, G.L.; Del Rio, A.; Varchi, G. A new avenue toward androgen receptor pan-antagonists: C2 sterically hindered substitution of hydroxy-propanamides. J. Med. Chem., 2014, 57(17), 7263-7279.
[http://dx.doi.org/10.1021/jm5005122] [PMID: 25121586]
[28]
Balbas, M.D.; Evans, M.J.; Hosfield, D.J.; Wongvipat, J.; Arora, V.K.; Watson, P.A.; Chen, Y.; Greene, G.L.; Shen, Y.; Sawyers, C.L. Overcoming mutation-based resistance to antiandrogens with rational drug design. eLife, 2013, 2e00499
[http://dx.doi.org/10.7554/eLife.00499] [PMID: 23580326]
[29]
Bohl, C.E.; Gao, W.; Miller, D.D.; Bell, C.E.; Dalton, J.T. Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proc. Natl. Acad. Sci. USA, 2005, 102(17), 6201-6206.
[http://dx.doi.org/10.1073/pnas.0500381102] [PMID: 15833816]
[30]
Chen, Y.; Clegg, N.J.; Scher, H.I. Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncol., 2009, 10(10), 981-991.
[http://dx.doi.org/10.1016/S1470-2045(09)70229-3] [PMID: 19796750]
[31]
Kolvenbag, G.J.; Blackledge, G.R.; Gotting-Smith, K. Bicalutamide (Casodex) in the treatment of prostate cancer: history of clinical development. Prostate, 1998, 34(1), 61-72.
[http://dx.doi.org/10.1002/(SICI)1097-0045(19980101)34:1<61:AID-PROS8>3.0.CO;2-N] [PMID: 9428389]
[32]
Heidenreich, A.; Bastian, P.J.; Bellmunt, J.; Bolla, M.; Joniau, S.; van der Kwast, T.; Mason, M.; Matveev, V.; Wiegel, T.; Zattoni, F.; Mottet, N. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur. Urol., 2014, 65(2), 467-479.
[http://dx.doi.org/10.1016/j.eururo.2013.11.002] [PMID: 24321502]
[33]
Veldscholte, J.; Ris-Stalpers, C.; Kuiper, G.G.; Jenster, G.; Berrevoets, C.; Claassen, E.; van Rooij, H.C.; Trapman, J.; Brinkmann, A.O.; Mulder, E. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem. Biophys. Res. Commun., 1990, 173(2), 534-540.
[http://dx.doi.org/10.1016/S0006-291X(05)80067-1] [PMID: 2260966]
[34]
Zuo, M.; Xu, X.; Xie, Z.; Ge, R.; Zhang, Z.; Li, Z.; Bian, J. Design and synthesis of indoline thiohydantoin derivatives based on enzalutamide as antiproliferative agents against prostate cancer. Eur. J. Med. Chem., 2017, 125, 1002-1022.
[http://dx.doi.org/10.1016/j.ejmech.2016.10.049] [PMID: 27810589]
[35]
Tran, C.; Ouk, S.; Clegg, N.J.; Chen, Y.; Watson, P.A.; Arora, V.; Wongvipat, J.; Smith-Jones, P.M.; Yoo, D.; Kwon, A. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science, 2009, 324(5928), 787-790.
[http://dx.doi.org/10.1126/science.1168175] [PMID: 19359544]
[36]
Scher, H.I.; Beer, T.M.; Higano, C.S.; Anand, A.; Taplin, M.E.; Efstathiou, E.; Rathkopf, D.; Shelkey, J.; Yu, E.Y.; Alumkal, J.; Hung, D.; Hirmand, M.; Seely, L.; Morris, M.J.; Danila, D.C.; Humm, J.; Larson, S.; Fleisher, M.; Sawyers, C.L. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet, 2010, 375(9724), 1437-1446.
[http://dx.doi.org/10.1016/S0140-6736(10)60172-9] [PMID: 20398925]
[37]
Beer, T.M.; Armstrong, A.J.; Rathkopf, D.E.; Loriot, Y.; Sternberg, C.N.; Higano, C.S.; Iversen, P.; Bhattacharya, S.; Carles, J.; Chowdhury, S.; Davis, I.D.; de Bono, J.S.; Evans, C.P.; Fizazi, K.; Joshua, A.M.; Kim, C.S.; Kimura, G.; Mainwaring, P.; Mansbach, H.; Miller, K.; Noonberg, S.B.; Perabo, F.; Phung, D.; Saad, F.; Scher, H.I.; Taplin, M.E.; Venner, P.M.; Tombal, B. Enzalutamide in metastatic prostate cancer before chemotherapy. N. Engl. J. Med., 2014, 371(5), 424-433.
[http://dx.doi.org/10.1056/NEJMoa1405095] [PMID: 24881730]
[38]
Scher, H.I.; Fizazi, K.; Saad, F.; Taplin, M-E.; Sternberg, C.N.; Miller, K.; de Wit, R.; Mulders, P.; Chi, K.N.; Shore, N.D.; Armstrong, A.J.; Flaig, T.W.; Fléchon, A.; Mainwaring, P.; Fleming, M.; Hainsworth, J.D.; Hirmand, M.; Selby, B.; Seely, L.; de Bono, J.S. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med., 2012, 367(13), 1187-1197.
[http://dx.doi.org/10.1056/NEJMoa1207506] [PMID: 22894553]
[39]
Shore, N.D.; Chowdhury, S.; Villers, A.; Klotz, L.; Siemens, D.R.; Phung, D.; van Os, S.; Hasabou, N.; Wang, F.; Bhattacharya, S.; Heidenreich, A. Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study. Lancet Oncol., 2016, 17(2), 153-163.
[http://dx.doi.org/10.1016/S1470-2045(15)00518-5] [PMID: 26774508]
[40]
Siemens, D.R.; Klotz, L.; Heidenreich, A.; Chowdhury, S.; Villers, A.; Baron, B.; van Os, S.; Hasabou, N.; Wang, F.; Lin, P.; Shore, N.D. Efficacy and safety of enzalutamide vs bicalutamide in younger and older patients with metastatic castration resistant prostate cancer in the TERRAIN trial. J. Urol., 2018, 199(1), 147-154.
[http://dx.doi.org/10.1016/j.juro.2017.08.080] [PMID: 28827103]
[41]
Joseph, J.D.; Lu, N.; Qian, J.; Sensintaffar, J.; Shao, G.; Brigham, D.; Moon, M.; Maneval, E.C.; Chen, I.; Darimont, B.; Hager, J.H. A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. Cancer Discov., 2013, 3(9), 1020-1029.
[http://dx.doi.org/10.1158/2159-8290.CD-13-0226] [PMID: 23779130]
[42]
Korpal, M.; Korn, J.M.; Gao, X.; Rakiec, D.P.; Ruddy, D.A.; Doshi, S.; Yuan, J.; Kovats, S.G.; Kim, S.; Cooke, V.G.; Monahan, J.E.; Stegmeier, F.; Roberts, T.M.; Sellers, W.R.; Zhou, W.; Zhu, P. An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). Cancer Discov., 2013, 3(9), 1030-1043.
[http://dx.doi.org/10.1158/2159-8290.CD-13-0142] [PMID: 23842682]
[43]
Arora, V.K.; Schenkein, E.; Murali, R.; Subudhi, S.K.; Wongvipat, J.; Balbas, M.D.; Shah, N.; Cai, L.; Efstathiou, E.; Logothetis, C.; Zheng, D.; Sawyers, C.L. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell, 2013, 155(6), 1309-1322.
[http://dx.doi.org/10.1016/j.cell.2013.11.012] [PMID: 24315100]
[44]
Antonarakis, E.S.; Lu, C.; Wang, H.; Luber, B.; Nakazawa, M.; Roeser, J.C.; Chen, Y.; Mohammad, T.A.; Chen, Y.; Fedor, H.L.; Lotan, T.L.; Zheng, Q.; De Marzo, A.M.; Isaacs, J.T.; Isaacs, W.B.; Nadal, R.; Paller, C.J.; Denmeade, S.R.; Carducci, M.A.; Eisenberger, M.A.; Luo, J. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N. Engl. J. Med., 2014, 371(11), 1028-1038.
[http://dx.doi.org/10.1056/NEJMoa1315815] [PMID: 25184630]
[45]
Pippione, A.C.; Boschi, D.; Pors, K.; Oliaro-Bosso, S.; Lolli, M.L. Androgen-AR axis in primary and metastatic prostate cancer: chasing steroidogenic enzymes for therapeutic intervention. J. Cancer Metastasis Treat., 2017, 3(12), 328.
[http://dx.doi.org/10.20517/2394-4722.2017.44]
[46]
Crona, D.J.; Whang, Y.E. Posterior reversible encephalopathy syndrome induced by enzalutamide in a patient with castration-resistant prostate cancer. Invest. New Drugs, 2015, 33(3), 751-754.
[http://dx.doi.org/10.1007/s10637-014-0193-3] [PMID: 25467090]
[47]
Smith, M.R.; Saad, F.; Chowdhury, S.; Oudard, S.; Hadaschik, B.A.; Graff, J.N.; Olmos, D.; Mainwaring, P.N.; Lee, J.Y.; Uemura, H. Apalutamide treatment and metastasis-free survival in prostate cancer. N. Engl. J. Med., 2018, 378(15), 1408-1418.
[http://dx.doi.org/ 10.1056/NEJMoa1715546] [PMID: 29420164]
[48]
Moilanen, A-M.; Riikonen, R.; Oksala, R.; Ravanti, L.; Aho, E.; Wohlfahrt, G.; Nykänen, P.S.; Törmäkangas, O.P.; Palvimo, J.J.; Kallio, P.J. Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies. Sci. Rep., 2015, 5(1), 12007.
[http://dx.doi.org/10.1038/srep12007] [PMID: 26137992]
[49]
Fizazi, K.; Albiges, L.; Loriot, Y.; Massard, C. ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer. Expert Rev. Anticancer Ther., 2015, 15(9), 1007-1017.
[http://dx.doi.org/10.1586/14737140.2015.1081566] [PMID: 26313416]
[50]
Shore, N.D. Darolutamide (ODM-201) for the treatment of prostate cancer. Expert Opin. Pharmacother., 2017, 18(9), 945-952.
[http://dx.doi.org/10.1080/14656566.2017.1329820] [PMID: 28490267]
[51]
Fizazi, K.; Massard, C.; Bono, P.; Jones, R.; Kataja, V.; James, N.; Garcia, J.A.; Protheroe, A.; Tammela, T.L.; Elliott, T.; Mattila, L.; Aspegren, J.; Vuorela, A.; Langmuir, P.; Mustonen, M. ARADES study group.Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial. Lancet Oncol., 2014, 15(9), 975-985.
[http://dx.doi.org/10.1016/S1470-2045(14)70240-2] [PMID: 24974051]
[52]
Andersen, R.J.; Mawji, N.R.; Wang, J.; Wang, G.; Haile, S.; Myung, J-K.; Watt, K.; Tam, T.; Yang, Y.C.; Bañuelos, C.A.; Williams, D.E.; McEwan, I.J.; Wang, Y.; Sadar, M.D. Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell, 2010, 17(6), 535-546.
[http://dx.doi.org/10.1016/j.ccr.2010.04.027] [PMID: 20541699]
[53]
Ito, Y.; Sadar, M.D. Enzalutamide and blocking androgen receptor in advanced prostate cancer: lessons learnt from the history of drug development of antiandrogens. Res. Rep. Urol., 2018, 10, 23-32.
[http://dx.doi.org/10.2147/RRU.S157116] [PMID: 29497605]
[54]
Gunther, J.R.; Parent, A.A.; Katzenellenbogen, J.A. Alternative inhibition of androgen receptor signaling: peptidomimetic pyrimidines as direct androgen receptor/coactivator disruptors. ACS Chem. Biol., 2009, 4(6), 435-440.
[http://dx.doi.org/10.1021/cb900043e] [PMID: 19441848]
[55]
Hsu, C-L.; Liu, J-S.; Lin, T-W.; Chang, Y-H.; Kuo, Y-C.; Lin, A-C.; Ting, H-J.; Pang, S-T.; Lee, L-Y.; Ma, W-L.; Lin, C.C.; Wu, W.G. Characterization of a novel androgen receptor (AR) coregulator RIPK1 and related chemicals that suppress AR-mediated prostate cancer growth via peptide and chemical screening. Oncotarget, 2017, 8(41), 69508-69519.
[http://dx.doi.org/10.18632/oncotarget.17843] [PMID: 29050220]
[56]
Féau, C.; Arnold, L.A.; Kosinski, A.; Zhu, F.; Connelly, M.; Guy, R.K. Novel flufenamic acid analogues as inhibitors of androgen receptor mediated transcription. ACS Chem. Biol., 2009, 4(10), 834-843.
[http://dx.doi.org/10.1021/cb900143a] [PMID: 19645433]
[57]
Munuganti, R.S.N.N.; Hassona, M.D.H.H.; Leblanc, E.; Frewin, K.; Singh, K.; Ma, D.; Ban, F.; Hsing, M.; Adomat, H.; Lallous, N.; Andre, C.; Jonadass, J.P.; Zoubeidi, A.; Young, R.N.; Guns, E.T.; Rennie, P.S.; Cherkasov, A. Identification of a potent antiandrogen that targets the BF3 site of the androgen receptor and inhibits enzalutamide-resistant prostate cancer. Chem. Biol., 2014, 21(11), 1476-1485.
[http://dx.doi.org/10.1016/j.chembiol.2014.09.012] [PMID: 25459660]
[58]
Zhang, Y.; Mantravadi, P.K.; Jobbagy, S.; Bao, W.; Koh, J.T. Antagonizing the Androgen Receptor with a Biomimetic Acyltransferase. ACS Chem. Biol., 2016, 11(10), 2797-2802.
[http://dx.doi.org/10.1021/acschembio.6b00659] [PMID: 27548116]
[59]
Li, H.; Ban, F.; Dalal, K.; Leblanc, E.; Frewin, K.; Ma, D.; Adomat, H.; Rennie, P.S.; Cherkasov, A. Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor. J. Med. Chem., 2014, 57(15), 6458-6467.
[http://dx.doi.org/10.1021/jm500802j] [PMID: 25062331]
[60]
Ivachtchenko, A.V.; Ivanenkov, Y.A.; Mitkin, O.D.; Vorobiev, A.A.; Kuznetsova, I.V.; Shevkun, N.A.; Koryakova, A.G.; Karapetian, R.N.; Trifelenkov, A.S.; Kravchenko, D.V.; Veselov, M.S.; Chufarova, N.V. Design, synthesis and biological evaluation of novel 5-oxo-2-thioxoimidazolidine derivatives as potent androgen receptor antagonists. Eur. J. Med. Chem., 2015, 99, 51-66.
[http://dx.doi.org/10.1016/j.ejmech.2015.05.039] [PMID: 26046313]
[61]
Xu, X.; Ge, R.; Li, L.; Wang, J.; Lu, X.; Xue, S.; Chen, X.; Li, Z.; Bian, J. Exploring the tetrahydroisoquinoline thiohydantoin scaffold blockade the androgen receptor as potent anti-prostate cancer agents. Eur. J. Med. Chem., 2018, 143, 1325-1344.
[http://dx.doi.org/10.1016/j.ejmech.2017.10.031] [PMID: 29117897]
[62]
Ferroni, C.; Pepe, A.; Kim, Y.S.; Lee, S.; Guerrini, A.; Parenti, M.D.; Tesei, A.; Zamagni, A.; Cortesi, M.; Zaffaroni, N.; De Cesare, M.; Beretta, G.L.; Trepel, J.B.; Malhotra, S.V.; Varchi, G. 1,4-substituted triazoles as nonsteroidal anti-androgens for prostate cancer treatment. J. Med. Chem., 2017, 60(7), 3082-3093.
[http://dx.doi.org/10.1021/acs.jmedchem.7b00105] [PMID: 28272894]
[63]
Guo, Z.; Yang, X.; Sun, F.; Jiang, R.; Linn, D.E.; Chen, H.; Chen, H.; Kong, X.; Melamed, J.; Tepper, C.G.; Kung, H.J.; Brodie, A.M.; Edwards, J.; Qiu, Y. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res., 2009, 69(6), 2305-2313.
[http://dx.doi.org/10.1158/0008-5472.CAN-08-3795] [PMID: 19244107]
[64]
Johnson, J.K.; Skoda, E.M.; Zhou, J.; Parrinello, E.; Wang, D.; O’Malley, K.; Eyer, B.R.; Kazancioglu, M.; Eisermann, K.; Johnston, P.A.; Nelson, J.B.; Wang, Z.; Wipf, P. Small molecule antagonists of the nuclear androgen receptor for the treatment of castration-resistant prostate cancer. ACS Med. Chem. Lett., 2016, 7(8), 785-790.
[http://dx.doi.org/10.1021/acsmedchemlett.6b00186] [PMID: 27563404]
[65]
Balog, A.; Rampulla, R.; Martin, G.S.; Krystek, S.R.; Attar, R.; Dell-John, J.; DiMarco, J.D.; Fairfax, D.; Gougoutas, J.; Holst, C.L.; Nation, A.; Rizzo, C.; Rossiter, L.M.; Schweizer, L.; Shan, W.; Spergel, S.; Spires, T.; Cornelius, G.; Gottardis, M.; Trainor, G.; Vite, G.D.; Salvati, M.E. Discovery of BMS-641988, a novel androgen receptor antagonist for the treatment of prostate cancer. ACS Med. Chem. Lett., 2015, 6(8), 908-912.
[http://dx.doi.org/10.1021/acsmedchemlett.5b00173] [PMID: 26288692]
[66]
Song, C-H.; Yang, S.H.; Park, E.; Cho, S.H.; Gong, E-Y.; Khadka, D.B.; Cho, W-J.; Lee, K. Structure-based virtual screening and identification of a novel androgen receptor antagonist. J. Biol. Chem., 2012, 287(36), 30769-30780.
[http://dx.doi.org/10.1074/jbc.M112.379107] [PMID: 22798067]
[67]
Zhao, C.; Choi, Y.H.; Khadka, D.B.; Jin, Y.; Lee, K.Y.; Cho, W.J. Design and synthesis of novel androgen receptor antagonists via molecular modeling. Bioorg. Med. Chem., 2016, 24(4), 789-801.
[http://dx.doi.org/10.1016/j.bmc.2015.12.047] [PMID: 26780832]
[68]
Gomez, L.; Kovac, J.R.; Lamb, D.J. CYP17A1 inhibitors in castration-resistant prostate cancer. Steroids, 2015, 95, 80-87.
[http://dx.doi.org/10.1016/j.steroids.2014.12.021] [PMID: 25560485]
[69]
Ammannagari, N.; George, S. Anti-androgen therapies for prostate cancer: a focused review. Am. J. Hematol. Oncol., 2014, 11(2), 15-19.
[70]
Li, Z.; Bishop, A.C.; Alyamani, M.; Garcia, J.A.; Dreicer, R.; Bunch, D.; Liu, J.; Upadhyay, S.K.; Auchus, R.J.; Sharifi, N. Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer. Nature, 2015, 523(7560), 347-351.
[http://dx.doi.org/10.1038/nature14406] [PMID: 26030522]
[71]
Imamura, Y.; Sadar, M.D. Androgen receptor targeted therapies in castration-resistant prostate cancer: Bench to clinic. Int. J. Urol., 2016, 23(8), 654-665.
[http://dx.doi.org/10.1111/iju.13137] [PMID: 27302572]
[72]
de Bono, J.S.; Logothetis, C.J.; Molina, A.; Fizazi, K.; North, S.; Chu, L.; Chi, K.N.; Jones, R.J.; Goodman, O.B., Jr; Saad, F.; Staffurth, J.N.; Mainwaring, P.; Harland, S.; Flaig, T.W.; Hutson, T.E.; Cheng, T.; Patterson, H.; Hainsworth, J.D.; Ryan, C.J.; Sternberg, C.N.; Ellard, S.L.; Fléchon, A.; Saleh, M.; Scholz, M.; Efstathiou, E.; Zivi, A.; Bianchini, D.; Loriot, Y.; Chieffo, N.; Kheoh, T.; Haqq, C.M.; Scher, H.I. COU-AA-301 Investigators.Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med., 2011, 364(21), 1995-2005.
[http://dx.doi.org/10.1056/NEJMoa1014618] [PMID: 21612468]
[73]
Clegg, N.J.; Wongvipat, J.; Joseph, J.D.; Tran, C.; Ouk, S.; Dilhas, A.; Chen, Y.; Grillot, K.; Bischoff, E.D.; Cai, L.; Aparicio, A.; Dorow, S.; Arora, V.; Shao, G.; Qian, J.; Zhao, H.; Yang, G.; Cao, C.; Sensintaffar, J.; Wasielewska, T.; Herbert, M.R.; Bonnefous, C.; Darimont, B.; Scher, H.I.; Smith-Jones, P.; Klang, M.; Smith, N.D.; De Stanchina, E.; Wu, N.; Ouerfelli, O.; Rix, P.J.; Heyman, R.A.; Jung, M.E.; Sawyers, C.L.; Hager, J.H. ARN-509: A novel antiandrogen for prostate cancer treatment. Cancer Res., 2012, 72(6), 1494-1503.
[http://dx.doi.org/10.1158/0008-5472.CAN-11-3948] [PMID: 22266222]
[74]
Yuan, X.; Cai, C.; Chen, S.; Chen, S.; Yu, Z.; Balk, S.P. Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis. Oncogene, 2014, 33(22), 2815-2825.
[http://dx.doi.org/10.1038/onc.2013.235] [PMID: 23752196]
[75]
van Soest, R.J.; van Royen, M.E.; de Morrée, E.S.; Moll, J.M.; Teubel, W.; Wiemer, E.A.C.; Mathijssen, R.H.J.; de Wit, R.; van Weerden, W.M. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer. Eur. J. Cancer, 2013, 49(18), 3821-3830.
[http://dx.doi.org/10.1016/j.ejca.2013.09.026] [PMID: 24200698]
[76]
Njar, V.C.O.; Brodie, A.M.H. Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer. J. Med. Chem., 2015, 58(5), 2077-2087.
[http://dx.doi.org/10.1021/jm501239f] [PMID: 25591066]
[77]
Bastos, D.A.; Antonarakis, E.S. Galeterone for the treatment of advanced prostate cancer: the evidence to date. Drug Des. Devel. Ther., 2016, 10, 2289-2297.
[http://dx.doi.org/10.2147/DDDT.S93941] [PMID: 27486306]
[78]
Montgomery, B.; Eisenberger, M.A.; Rettig, M.B.; Chu, F.; Pili, R.; Stephenson, J.J.; Vogelzang, N.J.; Koletsky, A.J.; Nordquist, L.T.; Edenfield, W.J.; Mamlouk, K.; Ferrante, K.J.; Taplin, M.E. Androgen receptor modulation optimized for response (ARMOR) phase I and II Studies: galeterone for the treatment of castration-resistant prostate cancer. Clin. Cancer Res., 2016, 22(6), 1356-1363.
[http://dx.doi.org/10.1158/1078-0432.CCR-15-1432] [PMID: 26527750]
[79]
Kwegyir-Afful, A.K.; Ramalingam, S.; Purushottamachar, P.; Ramamurthy, V.P.; Njar, V.C.O. Galeterone and VNPT55 induce proteasomal degradation of AR/AR-V7, induce significant apoptosis via cytochrome c release and suppress growth of castration resistant prostate cancer xenografts in vivo. Oncotarget, 2015, 6(29), 27440-27460.
[http://dx.doi.org/10.18632/oncotarget.4578] [PMID: 26196320]
[80]
Yu, Z.; Cai, C.; Gao, S.; Simon, N.I.; Shen, H.C.; Balk, S.P. Galeterone prevents androgen receptor binding to chromatin and enhances degradation of mutant androgen receptor. Clin. Cancer Res., 2014, 20(15), 4075-4085.
[http://dx.doi.org/10.1158/1078-0432.CCR-14-0292] [PMID: 24874833]
[81]
Larsen, M.; Hansen, C.H.; Rasmussen, T.B.; Islin, J.; Styrishave, B.; Olsen, L.; Jørgensen, F.S. Structure-based optimisation of non-steroidal cytochrome P450 17A1 inhibitors. Chem. Commun. (Camb.), 2017, 53(21), 3118-3121.
[http://dx.doi.org/10.1039/C6CC08680B] [PMID: 28245012]
[82]
Wang, M.; Fang, Y.; Gu, S.; Chen, F.; Zhu, Z.; Sun, X.; Zhu, J. Discovery of novel 1,2,3,4-tetrahydrobenzo[4, 5]thieno[2, 3-c]pyridine derivatives as potent and selective CYP17 inhibitors. Eur. J. Med. Chem., 2017, 132, 157-172.
[http://dx.doi.org/10.1016/j.ejmech.2017.03.037] [PMID: 28350999]
[83]
Toren, P.J.; Kim, S.; Pham, S.; Mangalji, A.; Adomat, H.; Guns, E.S.T.; Zoubeidi, A.; Moore, W.; Gleave, M.E. Anticancer activity of a novel selective CYP17A1 inhibitor in preclinical models of castrate-resistant prostate cancer. Mol. Cancer Ther., 2015, 14(1), 59-69.
[http://dx.doi.org/10.1158/1535-7163.MCT-14-0521] [PMID: 25351916]
[84]
Purushottamachar, P.; Kwegyir-Afful, A.K.; Martin, M.S.; Ramamurthy, V.P.; Ramalingam, S.; Njar, V.C.O. Identification of novel steroidal androgen receptor degrading agents inspired by galeterone 3β-imidazole carbamate. ACS Med. Chem. Lett., 2016, 7(7), 708-713.
[http://dx.doi.org/10.1021/acsmedchemlett.6b00137] [PMID: 27437082]
[85]
Levine, P.M.; Garabedian, M.J.; Kirshenbaum, K. Targeting the androgen receptor with steroid conjugates. J. Med. Chem., 2014, 57(20), 8224-8237.
[http://dx.doi.org/10.1021/jm500101h] [PMID: 24936953]
[86]
Tian, X.; He, Y.; Zhou, J. Progress in antiandrogen design targeting hormone binding pocket to circumvent mutation based resistance. Front. Pharmacol., 2015, 6, 57.
[http://dx.doi.org/10.3389/fphar.2015.00057] [PMID: 25852559]
[87]
Toure, M.; Crews, C.M. Small-Molecule PROTACS: new approaches to protein degradation. Angew. Chem. Int. Ed. Engl., 2016, 55(6), 1966-1973.
[http://dx.doi.org/10.1002/anie.201507978] [PMID: 26756721]
[88]
Churcher, I. Protac-induced protein degradation in drug discovery: breaking the rules or just making new ones? J. Med. Chem., 2018, 61(2), 444-452.
[http://dx.doi.org/10.1021/acs.jmedchem.7b01272] [PMID: 29144739]
[89]
Cromm, P.M.; Crews, C.M. Targeted protein degradation: from chemical biology to drug discovery. Cell Chem. Biol., 2017, 24(9), 1181-1190.
[http://dx.doi.org/10.1016/j.chembiol.2017.05.024] [PMID: 28648379]
[90]
Sakamoto, K.M.; Kim, K.B.; Kumagai, A.; Mercurio, F.; Crews, C.M.; Deshaies, R.J. Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proc. Natl. Acad. Sci. USA, 2001, 98(15), 8554-8559.
[http://dx.doi.org/10.1073/pnas.141230798] [PMID: 11438690]
[91]
Neklesa, T.K.; Winkler, J.D.; Crews, C.M. Targeted protein degradation by PROTACs. Pharmacol. Ther., 2017, 174, 138-144.
[http://dx.doi.org/10.1016/j.pharmthera.2017.02.027] [PMID: 28223226]
[92]
Schneekloth, A.R.; Pucheault, M.; Tae, H.S.; Crews, C.M. Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics. Bioorg. Med. Chem. Lett., 2008, 18(22), 5904-5908.
[http://dx.doi.org/10.1016/j.bmcl.2008.07.114] [PMID: 18752944]
[93]
Gustafson, J.L.; Neklesa, T.K.; Cox, C.S.; Roth, A.G.; Buckley, D.L.; Tae, H.S.; Sundberg, T.B.; Stagg, D.B.; Hines, J.; McDonnell, D.P.; Norris, J.D.; Crews, C.M. Small-molecule-mediated degradation of the androgen receptor through hydrophobic tagging. Angew. Chem. Int. Ed. Engl., 2015, 54(33), 9659-9662.
[http://dx.doi.org/10.1002/anie.201503720] [PMID: 26083457]
[94]
Tinworth, C.P.; Lithgow, H.; Churcher, I. Small molecule-mediated protein knockdown as a new approach to drug discovery. MedChemComm, 2016, 7(12), 2206-2216.
[http://dx.doi.org/10.1039/C6MD00347H]
[95]
Raina, K.; Lu, J.; Qian, Y.; Altieri, M.; Gordon, D.; Rossi, A.M.K.; Wang, J.; Chen, X.; Dong, H.; Siu, K.; Winkler, J.D.; Crew, A.P.; Crews, C.M.; Coleman, K.G. PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer. Proc. Natl. Acad. Sci. USA, 2016, 113(26), 7124-7129.
[http://dx.doi.org/10.1073/pnas.1521738113] [PMID: 27274052]
[96]
Raina, K.; Crews, C.M. Targeted protein knockdown using small molecule degraders. Curr. Opin. Chem. Biol., 2017, 39, 46-53.
[http://dx.doi.org/10.1016/j.cbpa.2017.05.016] [PMID: 28605671]
[97]
Itoh, Y.; Kitaguchi, R.; Ishikawa, M.; Naito, M.; Hashimoto, Y. Design, synthesis and biological evaluation of nuclear receptor-degradation inducers. Bioorg. Med. Chem., 2011, 19(22), 6768-6778.
[http://dx.doi.org/10.1016/j.bmc.2011.09.041] [PMID: 22014751]
[98]
Lai, A.C.; Crews, C.M. Induced protein degradation: an emerging drug discovery paradigm. Nat. Rev. Drug Discov., 2017, 16(2), 101-114.
[http://dx.doi.org/10.1038/nrd.2016.211] [PMID: 27885283]
[99]
Neklesa, T.; Snyder, L. B.; Willard, R. R.; Vitale, N.; Raina, K.; Pizzano, J.; Gordon, D. A.; Bookbinder, M.; Macaluso, J.; Dong, H. An Oral Androgen Receptor PROTAC Degrader for Prostate Cancer, J. of Clin. Oncol., 36(6_suppl), 381, 2018..
[http://dx.doi.org/10.1200/JCO.2018.36.6_suppl.381]
[100]
Bradbury, R.H.; Hales, N.J.; Rabow, A.A.; Walker, G.E.; Acton, D.G.; Andrews, D.M.; Ballard, P.; Brooks, N.A.N.; Colclough, N.; Girdwood, A.; Hancox, U.J.; Jones, O.; Jude, D.; Loddick, S.A.; Mortlock, A.A. Small-molecule androgen receptor downregulators as an approach to treatment of advanced prostate cancer. Bioorg. Med. Chem. Lett., 2011, 21(18), 5442-5445.
[http://dx.doi.org/10.1016/j.bmcl.2011.06.122] [PMID: 21782422]
[101]
Omlin, A.; Jones, R.J.; van der Noll, R.; Satoh, T.; Niwakawa, M.; Smith, S.A.; Graham, J.; Ong, M.; Finkelman, R.D.; Schellens, J.H.M.; Zivi, A.; Crespo, M.; Riisnaes, R.; Nava-Rodrigues, D.; Malone, M.D.; Dive, C.; Sloane, R.; Moore, D.; Alumkal, J.J.; Dymond, A.; Dickinson, P.A.; Ranson, M.; Clack, G.; de Bono, J.; Elliott, T. AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer - results of two parallel first-in-human phase I studies. Invest. New Drugs, 2015, 33(3), 679-690.
[http://dx.doi.org/10.1007/s10637-015-0235-5] [PMID: 25920479]
[102]
Yamashita, S.; Lai, K-P.; Chuang, K-L.; Xu, D.; Miyamoto, H.; Tochigi, T.; Pang, S-T.; Li, L.; Arai, Y.; Kung, H-J.; Yeh, S.; Chang, C. ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors. Neoplasia, 2012, 14(1), 74-83.
[http://dx.doi.org/10.1593/neo.111436] [PMID: 22355276]
[103]
Wang, R.; Lin, W.; Lin, C.; Li, L.; Sun, Y.; Chang, C. ASC-J9(®) suppresses castration resistant prostate cancer progression via degrading the enzalutamide-induced androgen receptor mutant AR-F876L. Cancer Lett., 2016, 379(1), 154-160.
[http://dx.doi.org/10.1016/j.canlet.2016.05.018] [PMID: 27233475]
[104]
Liu, C.; Lou, W.; Zhu, Y.; Nadiminty, N.; Schwartz, C.T.; Evans, C.P.; Gao, A.C. Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer. Clin. Cancer Res., 2014, 20(12), 3198-3210.
[http://dx.doi.org/10.1158/1078-0432.CCR-13-3296] [PMID: 24740322]
[105]
Ndagi, U.; Mhlongo, N.; Soliman, M.E. Metal complexes in cancer therapy - an update from drug design perspective. Drug Des. Devel. Ther., 2017, 11, 599-616.
[http://dx.doi.org/10.2147/DDDT.S119488] [PMID: 28424538]
[106]
Sonnenburg, D.W.; Morgans, A.K. Emerging therapies in metastatic prostate cancer. Curr. Oncol. Rep., 2018, 20(6), 46.
[http://dx.doi.org/10.1007/s11912-018-0692-z] [PMID: 29644451]
[107]
Cossa, G.; Gatti, L.; Zunino, F.; Perego, P. Strategies to improve the efficacy of platinum compounds. Curr. Med. Chem., 2009, 16(19), 2355-2365.
[http://dx.doi.org/10.2174/092986709788682083] [PMID: 19601785]
[108]
Masood, I.; Kiani, M.H.; Ahmad, M.; Masood, M.I.; Sadaquat, H. Major contributions towards finding a cure for cancer through chemotherapy: A historical review. Tumori, 2016, 102(1), 6-17.
[http://dx.doi.org/10.5301/tj.5000387] [PMID: 26350183]
[109]
Shah, N.; Dizon, D.S. New-generation platinum agents for solid tumors. Future Oncol., 2009, 5(1), 33-42.
[http://dx.doi.org/10.2217/14796694.5.1.33] [PMID: 19243296]
[110]
Huxley, M.; Sanchez-Cano, C.; Browning, M.J.; Navarro-Ranninger, C.; Quiroga, A.G.; Rodger, A.; Hannon, M.J. An androgenic steroid delivery vector that imparts activity to a non-conventional platinum(II) metallo-drug. Dalton Trans., 2010, 39(47), 11353-11364.
[http://dx.doi.org/10.1039/c0dt00838a] [PMID: 21031218]
[111]
Eckschlager, T.; Plch, J.; Stiborova, M.; Hrabeta, J. Histone deacetylase inhibitors as anticancer drugs. Int. J. Mol. Sci., 2017, 18(7), 1414.
[http://dx.doi.org/10.3390/ijms18071414] [PMID: 28671573]
[112]
Gryder, B.E.; Akbashev, M.J.; Rood, M.K.; Raftery, E.D.; Meyers, W.M.; Dillard, P.; Khan, S.; Oyelere, A.K. Selectively targeting prostate cancer with antiandrogen equipped histone deacetylase inhibitors. ACS Chem. Biol., 2013, 8(11), 2550-2560.
[http://dx.doi.org/10.1021/cb400542w] [PMID: 24004176]
[113]
Cogan, P.S.; Koch, T.H. Studies of targeting and intracellular trafficking of an anti-androgen doxorubicin-formaldehyde conjugate in PC-3 prostate cancer cells bearing androgen receptor-GFP chimera. J. Med. Chem., 2004, 47(23), 5690-5699.
[http://dx.doi.org/10.1021/jm0495226] [PMID: 15509168]
[114]
Zou, Z.; Chang, H.; Li, H.; Wang, S. Induction of reactive oxygen species: an emerging approach for cancer therapy. Apoptosis, 2017, 22(11), 1321-1335.
[http://dx.doi.org/10.1007/s10495-017-1424-9] [PMID: 28936716]
[115]
Kataoka, H.; Nishie, H.; Hayashi, N.; Tanaka, M.; Nomoto, A.; Yano, S.; Joh, T. New photodynamic therapy with next-generation photosensitizers. Ann. Transl. Med., 2017, 5(8), 183-183.
[http://dx.doi.org/10.21037/atm.2017.03.59] [PMID: 28616398]
[116]
Rapozzi, V.; Ragno, D.; Guerrini, A.; Ferroni, C.; della Pietra, E.; Cesselli, D.; Castoria, G.; Di Donato, M.; Saracino, E.; Benfenati, V.; Varchi, G. androgen receptor targeted conjugate for bimodal photodynamic therapy of prostate cancer in vitro. Bioconjug. Chem., 2015, 26(8), 1662-1671.
[http://dx.doi.org/10.1021/acs.bioconjchem.5b00261] [PMID: 26108715]
[117]
Sortino, S. Light-controlled nitric oxide delivering molecular assemblies. Chem. Soc. Rev., 2010, 39(8), 2903-2913.
[http://dx.doi.org/10.1039/b908663n] [PMID: 20556272]
[118]
Rapozzi, V.; Varchi, G.; Della Pietra, E.; Ferroni, C.; Xodo, L.E. A photodynamic bifunctional conjugate for prostate cancer: an in vitro mechanistic study. Invest. New Drugs, 2017, 35(1), 115-123.
[http://dx.doi.org/10.1007/s10637-016-0396-x] [PMID: 27726093]

Rights & Permissions Print Cite
© 2025 Bentham Science Publishers | Privacy Policy
Request history8.2.27PHP Version763msRequest Duration28MBMemory UsageGET article/{article_id}/{param?}Route
  • warninglog[13:31:41] LOG.warning: Optional parameter $article_id declared before required parameter $request i...
  • warninglog[13:31:41] LOG.warning: trim(): Passing null to parameter #1 ($string) of type string is deprecated ...
  • warninglog[13:31:41] LOG.warning: Function strftime() is deprecated in /home/alphaeurekaselec/public_html/stor...
  • Booting (142ms)time
  • Application (621ms)time
  • 1 x Application (81.4%)
    621ms
    1 x Booting (18.6%)
    142ms
    14 templates were rendered
    • articlearticle.blade.php#?blade
    • includes.article_top_bannerarticle_top_banner.blade.php#?blade
    • includes.article_referencearticle_reference.blade.php#?blade
    • export_citation_formexport_citation_form.blade.php#?blade
    • includes.article_bottom_bannerarticle_bottom_banner.blade.php#?blade
    • includes.inc_related_journalsinc_related_journals.blade.php#?blade
    • includes.inc_related_ebooksinc_related_ebooks.blade.php#?blade
    • includes.journal_rightmenujournal_rightmenu.blade.php#?blade
    • includes.journal_right_bannerjournal_right_banner.blade.php#?blade
    • layouts.appapp.blade.php#?blade
    • layouts._login_access_login_access.blade.php#?blade
    • layouts._header_header.blade.php#?blade
    • layouts._main_menu_main_menu.blade.php#?blade
    • layouts._footer_menu_footer_menu.blade.php#?blade
    uri
    GET article/{article_id}/{param?}
    middleware
    web, check_user_access
    controller
    App\Http\Controllers\ArticleController@GetArticleDetails
    namespace
    App\Http\Controllers
    where
    as
    article
    file
    app/Http/Controllers/ArticleController.php:1974-2510
    37 statements were executed, 4 of which were duplicates, 33 unique. Show only duplicated495ms
    • Connection Establishedalphaeurekaselec_live_10_06_2022UserAccessCheck.php#24
      Backtrace
      • 9. middleware::check_user_access:24
      • 10. vendor/laravel/framework/src/Illuminate/Pipeline/Pipeline.php:183
      • 11. vendor/laravel/framework/src/Illuminate/Routing/Middleware/SubstituteBindings.php:50
      • 12. vendor/laravel/framework/src/Illuminate/Pipeline/Pipeline.php:183
      • 13. vendor/laravel/framework/src/Illuminate/Foundation/Http/Middleware/VerifyCsrfToken.php:88
    • INSERT INTO visitor_ip_address (ip_address,visitor_agent,visitor_count, created_on,updated_on) VALUES ('314383442','',1,1739971901,1739971901) ON DUPLICATE KEY UPDATE visitor_count=visitor_count + 1, updated_on=1739971901
      4.07msalphaeurekaselec_live_10_06_2022UserAccessCheck.php#24
      Backtrace
      • 11. middleware::check_user_access:24
      • 12. vendor/laravel/framework/src/Illuminate/Pipeline/Pipeline.php:183
      • 13. vendor/laravel/framework/src/Illuminate/Routing/Middleware/SubstituteBindings.php:50
      • 14. vendor/laravel/framework/src/Illuminate/Pipeline/Pipeline.php:183
      • 15. vendor/laravel/framework/src/Illuminate/Foundation/Http/Middleware/VerifyCsrfToken.php:88
    • INSERT INTO visitor_ip_address_detail (ip_address,visitor_url,visitor_count, created_on,updated_on) VALUES ('314383442','/article/93022',1,1739971901,1739971901)
      240μsalphaeurekaselec_live_10_06_2022UserAccessCheck.php#27
      Backtrace
      • 11. middleware::check_user_access:27
      • 12. vendor/laravel/framework/src/Illuminate/Pipeline/Pipeline.php:183
      • 13. vendor/laravel/framework/src/Illuminate/Routing/Middleware/SubstituteBindings.php:50
      • 14. vendor/laravel/framework/src/Illuminate/Pipeline/Pipeline.php:183
      • 15. vendor/laravel/framework/src/Illuminate/Foundation/Http/Middleware/VerifyCsrfToken.php:88
    • (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_journal_volume_trail WHERE to_ip >= 314383442 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 314383442) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_journal_volume_corporate WHERE to_ip >= 314383442 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 314383442) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_journal_volume_token WHERE to_ip >= 314383442 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 314383442) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_ebook_volume_trail WHERE to_ip >= 314383442 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 314383442) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_ebook_volume_corporate WHERE to_ip >= 314383442 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 314383442) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_ebook_volume_token WHERE to_ip >= 314383442 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 314383442) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_issue_trail WHERE to_ip >= 314383442 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 314383442) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_issue_corporate WHERE to_ip >= 314383442 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 314383442) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_issue_token WHERE to_ip >= 314383442 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 314383442) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_article_trail WHERE to_ip >= 314383442 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 314383442) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_article_corporate WHERE to_ip >= 314383442 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 314383442) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_article_token WHERE to_ip >= 314383442 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 314383442) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_chapter_trail WHERE to_ip >= 314383442 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 314383442) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_chapter_corporate WHERE to_ip >= 314383442 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 314383442) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_chapter_token WHERE to_ip >= 314383442 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 314383442) union (select `user_id`, `to_ip`, `from_ip` from (select user_id, to_ip, from_ip FROM user_access_disease_corporate WHERE to_ip >= 314383442 ORDER BY to_ip ASC LIMIT 1) as `tjv` where `from_ip` <= 314383442) limit 1
      21.56msalphaeurekaselec_live_10_06_2022UserAccess.php#784
      Bindings
      • 0: 314383442
      • 1: 314383442
      • 2: 314383442
      • 3: 314383442
      • 4: 314383442
      • 5: 314383442
      • 6: 314383442
      • 7: 314383442
      • 8: 314383442
      • 9: 314383442
      • 10: 314383442
      • 11: 314383442
      • 12: 314383442
      • 13: 314383442
      • 14: 314383442
      • 15: 314383442
      Backtrace
      • 14. app/Models/UserAccess/UserAccess.php:784
      • 15. middleware::check_user_access:114
      • 16. vendor/laravel/framework/src/Illuminate/Pipeline/Pipeline.php:183
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Middleware/SubstituteBindings.php:50
      • 18. vendor/laravel/framework/src/Illuminate/Pipeline/Pipeline.php:183
    • SELECT at.type_name, p.copyright, p.publisher_location,m.month,y.year, a.publish_on, a.nid article_nid,a.article_id, a.pmid, a.issue_id, a.title, a.abstract,a.podcast,a.altmetric_score,a.altmetric_url,a.kudos_url, a.page_count, a.first_page, a.elocator, a.last_page, i.publication_date, a.file_name, a.file_path, a.doi, a.is_epub,a.epub_type, a.volume_id, a.is_uploaded, a.editor_choice, a.is_epub, j.image_file_name, a.article_no, a.art_type AS article_type, a.supplementary_filename,a.html_filename,a.prc_filename,a.epub_filename, a.graph_abs_lg_filename, a.graph_abs_sm_filename, a.oa_image_lg_filename, a.oa_image_sm_filename, j.journal_banner,a.animated_abstract,a.erratum_in,a.erratum_for, (CASE WHEN a.issue_id =0 THEN j.epub_price ELSE j.price END) AS sell_price, j.epub_price, j.nid AS jour_nid, j.title AS journal_title, j.issn, j.eissn,j.journal_id, j.subtitle AS jour_subtitle, v.volume_id,v.volume_name AS volume, v.year_id, i.title AS issue, i.month_id ,i.type issue_type, j.subtitle,j.formerly_title, ac.subtitle AS epub_title,a.crossmark_enabled,a.text_mining_urls,a.license_urls,a.created, a.receivedate, a.revisedate, a.acceptdate,js.js_title FROM article a LEFT JOIN article_section ac ON a.is_epub = ac.art_sec_id LEFT JOIN journal_section js ON a.js_id = js.js_id LEFT JOIN article_type at ON a.art_type = at.art_type_id LEFT JOIN issue i ON a.issue_id = i.issue_id LEFT JOIN month m ON m.id = i.month_id LEFT JOIN volume v ON v.volume_id = a.volume_id INNER JOIN year y ON y.id = v.year_id INNER JOIN journal j ON j.journal_id = a.journal_id INNER JOIN publisher p ON p.publisher_id = j.publisher_id WHERE a.article_id=93022
      1.78msalphaeurekaselec_live_10_06_2022Article.php#408
      Backtrace
      • 11. app/Models/Article.php:408
      • 12. app/Http/Controllers/ArticleController.php:2515
      • 13. app/Http/Controllers/ArticleController.php:2035
      • 14. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 15. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select * from `journal` where `journal_id` = 25 limit 1
      1.61msalphaeurekaselec_live_10_06_2022Journal.php#64
      Bindings
      • 0: 25
      Backtrace
      • 14. app/Models/Journal.php:64
      • 15. app/Http/Controllers/ArticleController.php:2516
      • 16. app/Http/Controllers/ArticleController.php:2035
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 18. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select count(*) as aggregate from (select j.nid as journal_nid,j.flyer_link,j.title ,j.issn,j.eissn,j.keyword, j.journal_id as journal_id, j.subtitle, j.image_file_name,j.description,j.journal_insight_url,j.doi from `subject_journal` as `sj` inner join `journal` as `j` on `j`.`journal_id` = `sj`.`journal_id` where j.journal_status=1 and subject_id IN (SELECT subject_id FROM subject_journal WHERE journal_id=25) and sj.journal_id!=25 group by `j`.`nid`) as `aggregate_table`
      2.12msalphaeurekaselec_live_10_06_2022Subject.php#200
      Backtrace
      • 16. app/Models/Subject.php:200
      • 17. app/Http/Controllers/ArticleController.php:2517
      • 18. app/Http/Controllers/ArticleController.php:2035
      • 19. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 20. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select j.nid as journal_nid,j.flyer_link,j.title ,j.issn,j.eissn,j.keyword, j.journal_id as journal_id, j.subtitle, j.image_file_name,j.description,j.journal_insight_url,j.doi from `subject_journal` as `sj` inner join `journal` as `j` on `j`.`journal_id` = `sj`.`journal_id` where j.journal_status=1 and subject_id IN (SELECT subject_id FROM subject_journal WHERE journal_id=25) and sj.journal_id!=25 group by `j`.`nid` order by `j`.`journal_id` asc limit 10 offset 0
      1.77msalphaeurekaselec_live_10_06_2022Subject.php#200
      Backtrace
      • 14. app/Models/Subject.php:200
      • 15. app/Http/Controllers/ArticleController.php:2517
      • 16. app/Http/Controllers/ArticleController.php:2035
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 18. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select count(*) as aggregate from (select v.nid as volume_id,e.nid,e.title,v.issn,v.eissn,v.isbn,v.eisbn,e.ebook_id, v.image_file_name,v.file_path,v.flyer_link,v.ebook_volume_id, v.volume_name,v.doi,v.year_id,v.introduction from `subject_ebook` as `se` inner join `ebook` as `e` on `e`.`ebook_id` = `se`.`ebook_id` inner join `ebook_volume` as `v` on `v`.`ebook_id` = `se`.`ebook_id` inner join `year` as `y` on `y`.`id` = `v`.`year_id` where subject_id IN (SELECT subject_id FROM subject_journal WHERE journal_id=25) and v.ebook_status='1' and y.year > 2020 group by `v`.`nid`) as `aggregate_table`
      85.55msalphaeurekaselec_live_10_06_2022Subject.php#220
      Backtrace
      • 16. app/Models/Subject.php:220
      • 17. app/Http/Controllers/ArticleController.php:2518
      • 18. app/Http/Controllers/ArticleController.php:2035
      • 19. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 20. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select v.nid as volume_id,e.nid,e.title,v.issn,v.eissn,v.isbn,v.eisbn,e.ebook_id, v.image_file_name,v.file_path,v.flyer_link,v.ebook_volume_id, v.volume_name,v.doi,v.year_id,v.introduction from `subject_ebook` as `se` inner join `ebook` as `e` on `e`.`ebook_id` = `se`.`ebook_id` inner join `ebook_volume` as `v` on `v`.`ebook_id` = `se`.`ebook_id` inner join `year` as `y` on `y`.`id` = `v`.`year_id` where subject_id IN (SELECT subject_id FROM subject_journal WHERE journal_id=25) and v.ebook_status='1' and y.year > 2020 group by `v`.`nid` order by `v`.`ebook_volume_id` desc limit 10 offset 0
      6.33msalphaeurekaselec_live_10_06_2022Subject.php#220
      Backtrace
      • 14. app/Models/Subject.php:220
      • 15. app/Http/Controllers/ArticleController.php:2518
      • 16. app/Http/Controllers/ArticleController.php:2035
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 18. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select * from `keywords` where `article_id` = '93022'
      1.36msalphaeurekaselec_live_10_06_2022Keywords.php#43
      Bindings
      • 0: 93022
      Backtrace
      • 13. app/Models/Keywords.php:43
      • 14. app/Http/Controllers/ArticleController.php:2519
      • 15. app/Http/Controllers/ArticleController.php:2035
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 17. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select * from `article_citation` where `article_id` = '93022'
      17.2msalphaeurekaselec_live_10_06_2022Article.php#1570
      Bindings
      • 0: 93022
      Backtrace
      • 13. app/Models/Article.php:1570
      • 14. app/Http/Controllers/ArticleController.php:2520
      • 15. app/Http/Controllers/ArticleController.php:2035
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 17. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select CONCAT_WS(' ',au.first_name, ' ', ifnull(au.initials,''), ' ', au.last_name) as authors, CONCAT(au.last_name, IFNULL(CONCAT(' ', au.initials), ''), ' ', au.first_name) AS authorsRIS, CONCAT_WS(' ',au.last_name, ' ', ifnull(au.initials,''), ' ', au.first_name) as authorsCiteAs, CONCAT_WS(' ',au.first_name, IFNULL(CONCAT(' ', au.initials), ''), IFNULL(CONCAT(' ', au.last_name), '')) as authorsmodal , `au`.*, `af`.`ror_id`, `af`.`institution`, `af`.`department`, `af`.`country`, `af`.`city`, `af`.`address`, (GROUP_CONCAT(TRIM(BOTH ', ' FROM CONCAT(ifnull(concat(af.institution,','),''), ifnull(concat(af.department,','),''), ifnull(concat(af.address,','),''), ifnull(concat(af.city,','),''), ifnull(concat(af.country,','),''), ifnull(concat(af.postal_code,','),''), ifnull(concat(af.phone,','),''), ifnull(concat(af.fax,','),''))) SEPARATOR '|')) as `author_affiliation`, (GROUP_CONCAT(TRIM(BOTH ', ' FROM CONCAT(ifnull(concat(af.web_view,','),''))) SEPARATOR '|')) as `web_view` from `author` as `au` left join `author_affiliation` as `af` on `au`.`author_id` = `af`.`author_id` where `au`.`article_id` = '93022' group by `au`.`author_id` order by `au`.`article_id` asc, `au`.`sequence` asc
      1.99msalphaeurekaselec_live_10_06_2022Author.php#86
      Bindings
      • 0: 93022
      Backtrace
      • 13. app/Models/Author.php:86
      • 14. app/Http/Controllers/ArticleController.php:2533
      • 15. app/Http/Controllers/ArticleController.php:2035
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 17. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select `bo`.* from `bundle_offer` as `bo` where `bo`.`bundle_status` = 'A' order by `bo`.`bundle_id` desc
      360μsalphaeurekaselec_live_10_06_2022BundleOffer.php#57
      Bindings
      • 0: A
      Backtrace
      • 13. app/Models/BundleOffer.php:57
      • 14. app/Http/Controllers/ArticleController.php:2535
      • 15. app/Http/Controllers/ArticleController.php:2035
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 17. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
    • select `subtitle` from `journal` where `continues_publication_journal` = 1
      1.28msalphaeurekaselec_live_10_06_2022Article.php#1960
      Bindings
      • 0: 1
      Backtrace
      • 13. app/Models/Article.php:1960
      • 14. app/Http/Controllers/ArticleController.php:2062
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • Select j.subtitle, v.volume_id as volume_id,v.year_id,y.year as year,v.volume_name, v.total_no_of_issues, i.issue_id as issue_id,i.title as issue, i.publication_date as issue_pub_date from journal j join volume v on j.journal_id = v.journal_id join issue i on v.volume_id = i.volume_id join article a on a.issue_id = i.issue_id join year y on v.year_id = y.id where j.journal_id = 25 and i.is_uploaded = 1 order by v.volume_name+0 desc, i.title+0 desc limit 1
      74.84msalphaeurekaselec_live_10_06_2022Issue.php#298
      Backtrace
      • 11. app/Models/Issue.php:298
      • 12. app/Http/Controllers/ArticleController.php:2068
      • 13. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 14. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select a.nid,a.publish_on, a.pmid,a.article_id,a.doi,j.journal_id,j.subtitle,v.volume_name,a.volume_id as volume_id, a.issue_id,a.title,first_page, last_page, page_count,abstract,ifnull(is_abstract,"y"),asec.title as article_section,at.type_name as article_type_name, a.article_id as ArticleID ,is_epub,epub_price,epub_type,a.created, y.year from `article` as `a` left join `article_section` as `asec` on `asec`.`art_sec_id` = `a`.`is_epub` left join `article_type` as `at` on `at`.`art_type_id` = `a`.`art_type` left join `journal` as `j` on `j`.`journal_id` = `a`.`journal_id` inner join `volume` as `v` on `a`.`volume_id` = `v`.`volume_id` inner join `year` as `y` on `v`.`year_id` = `y`.`id` where a.article_status != "W" and a.is_epub = 1 and a.journal_id = 25 and a.is_uploaded = 1 group by `a`.`article_id` order by `a`.`publish_on` desc
      112msalphaeurekaselec_live_10_06_2022Article.php#528
      Backtrace
      • 13. app/Models/Article.php:528
      • 14. app/Http/Controllers/ArticleController.php:2070
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select a.nid,a.publish_on, a.pmid,a.article_id,a.doi,j.journal_id,j.subtitle,v.volume_name,a.volume_id as volume_id, a.issue_id,a.title,first_page, last_page, page_count,abstract,ifnull(is_abstract,"y"),asec.title as article_section,at.type_name as article_type_name, a.article_id as ArticleID ,is_epub,epub_price,epub_type,a.created, y.year from `article` as `a` left join `article_section` as `asec` on `asec`.`art_sec_id` = `a`.`is_epub` left join `article_type` as `at` on `at`.`art_type_id` = `a`.`art_type` left join `journal` as `j` on `j`.`journal_id` = `a`.`journal_id` inner join `volume` as `v` on `a`.`volume_id` = `v`.`volume_id` inner join `year` as `y` on `v`.`year_id` = `y`.`id` where a.article_status != "W" and a.is_epub = 4 and a.journal_id = 25 and a.is_uploaded = 1 group by `a`.`article_id` order by `a`.`publish_on` desc
      49.31msalphaeurekaselec_live_10_06_2022Article.php#528
      Backtrace
      • 13. app/Models/Article.php:528
      • 14. app/Http/Controllers/ArticleController.php:2071
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select pdf, html, epub, prc from `article_metrics` where `article_id` = 93022 limit 1
      360μsalphaeurekaselec_live_10_06_2022Article.php#744
      Bindings
      • 0: 93022
      Backtrace
      • 14. app/Models/Article.php:744
      • 15. app/Http/Controllers/ArticleController.php:2091
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 17. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 18. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select * from content_by_diseases where content_id = 93022 and content_type = 'article' order by status desc limit 1
      440μsalphaeurekaselec_live_10_06_2022Article.php#751
      Backtrace
      • 11. app/Models/Article.php:751
      • 12. app/Http/Controllers/ArticleController.php:2094
      • 13. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 14. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select a.nid article_nid,a.title article_title,j.title journal_title from content_by_diseases cd inner join article a on a.article_id=cd.content_id inner join journal j on j.journal_id=a.journal_id where cd.pid = 16 and cd.sub_disease_id = 483 and content_id!=93022 and cd.content_type = 'article' order by rand() limit 20
      90.86msalphaeurekaselec_live_10_06_2022Article.php#769
      Backtrace
      • 11. app/Models/Article.php:769
      • 12. app/Http/Controllers/ArticleController.php:2098
      • 13. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 14. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select * from `node_meta` where `nid` = 165379 limit 1
      330μsalphaeurekaselec_live_10_06_2022Meta.php#30
      Bindings
      • 0: 165379
      Backtrace
      • 14. app/Models/Meta.php:30
      • 15. app/Http/Controllers/ArticleController.php:2101
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 17. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 18. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select `bo`.* from `bundle_offer` as `bo` where `bo`.`bundle_status` = 'A' order by `bo`.`bundle_id` desc
      330μsalphaeurekaselec_live_10_06_2022BundleOffer.php#57
      Bindings
      • 0: A
      Backtrace
      • 13. app/Models/BundleOffer.php:57
      • 14. app/Http/Controllers/ArticleController.php:2108
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select * from `tbl_ht_submission` as `h` where `h`.`subtitle` = 'CMC' and (h.proposal_closing_date = 0 OR TO_DAYS(FROM_UNIXTIME(h.proposal_closing_date)) >= TO_DAYS(NOW())) order by `h`.`manuscript` asc
      530μsalphaeurekaselec_live_10_06_2022Article.php#2025
      Bindings
      • 0: CMC
      Backtrace
      • 13. app/Models/Article.php:2025
      • 14. app/Http/Controllers/ArticleController.php:2112
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select count(*) as total_count, content_type_access_id as access_type from journal_access where content_type_id = '93022' and content_type = 'a' and ( (from_date <= CURDATE() and to_date >= CURDATE() and perpetual= 0) or (from_date is null and to_date is null and perpetual= 1) )
      510μsalphaeurekaselec_live_10_06_2022ContentAccess.php#647
      Backtrace
      • 11. app/Models/ContentAccess.php:647
      • 12. app/Http/Controllers/ArticleController.php:2186
      • 13. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 14. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select count(*) as total_count, content_type_access_id as access_type from journal_access where content_type_id = '9455' and content_type = 'i' and ( (from_date <= CURDATE() and to_date >= CURDATE() and perpetual= 0) or (from_date is null and to_date is null and perpetual= 1) )
      460μsalphaeurekaselec_live_10_06_2022ContentAccess.php#647
      Backtrace
      • 11. app/Models/ContentAccess.php:647
      • 12. app/Http/Controllers/ArticleController.php:2207
      • 13. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 14. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select count(*) as total_count, content_type_access_id as access_type from journal_access where content_type_id = '2572' and content_type = 'v' and ( (from_date <= CURDATE() and to_date >= CURDATE() and perpetual= 0) or (from_date is null and to_date is null and perpetual= 1) )
      420μsalphaeurekaselec_live_10_06_2022ContentAccess.php#647
      Backtrace
      • 11. app/Models/ContentAccess.php:647
      • 12. app/Http/Controllers/ArticleController.php:2231
      • 13. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 14. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • (select j.user_access_id,j.volume_id,j.user_id,j.from_ip,j.to_ip,j.type,j.track,"Trial Access" as access_base_text, CASE j.type WHEN 111 THEN true ELSE false END as terms_popup, "S" as content_download_type, null as restricted_user_access_key, null as restricted_user_access_type, CASE j.track WHEN 0 THEN false ELSE true END as tracksAccessByVolume,"volume" as access_level,"" as issue_id,"" as article_id from `user_access_journal_volume_trail` as `j` inner join `user_access_info` as `info` on `j`.`user_access_id` = `info`.`user_access_id` where ((j.from_ip <= 314383442 and j.to_ip >=314383442 )) and ((j.from_date <= 1739971901 and j.to_date >= 1739971901 and j.perpetual= 0) or (j.from_date is null and j.to_date is null and j.perpetual= 1)) and j.volume_id = 2572) union (select j.user_access_id,j.volume_id,j.user_id,j.from_ip,j.to_ip,j.type,j.track,"Subscribed" as access_base_text, false as terms_popup, "S" as content_download_type, null as restricted_user_access_key, null as restricted_user_access_type, CASE j.track WHEN 0 THEN false ELSE true END as tracksAccessByVolume,"volume" as access_level,"" as issue_id,"" as article_id from `user_access_journal_volume_corporate` as `j` inner join `user_access_info` as `info` on `j`.`user_access_id` = `info`.`user_access_id` where ((j.from_ip <= 314383442 and j.to_ip >=314383442 )) and ((j.from_date <= 1739971901 and j.to_date >= 1739971901 and j.perpetual= 0) or (j.from_date is null and j.to_date is null and j.perpetual= 1)) and j.volume_id = 2572) union (select j.user_access_id,j.volume_id,j.user_id,j.from_ip,j.to_ip,j.type,j.track,"Token Based Access" as access_base_text, false as terms_popup, "R" as content_download_type, j.uc_id as restricted_user_access_key, "v" as restricted_user_access_type, CASE j.track WHEN 0 THEN false ELSE true END as tracksAccessByVolume,"volume" as access_level,"" as issue_id,"" as article_id from `user_access_journal_volume_token` as `j` inner join `user_access_info` as `info` on `j`.`user_access_id` = `info`.`user_access_id` where ((j.from_ip <= 314383442 and j.to_ip >=314383442 )) and ((j.from_date <= 1739971901 and j.to_date >= 1739971901 and j.perpetual= 0) or (j.from_date is null and j.to_date is null and j.perpetual= 1)) and j.volume_id = 2572)
      6.74msalphaeurekaselec_live_10_06_2022UserAccess.php#1266
      Backtrace
      • 13. app/Models/UserAccess/UserAccess.php:1266
      • 14. app/Http/Controllers/ArticleController.php:2272
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • (select j.user_access_id,j.volume_id,j.user_id,j.from_ip,j.to_ip,j.type,j.track,"Trial Access" as access_base_text, CASE j.type WHEN 111 THEN true ELSE false END as terms_popup, "S" as content_download_type, null as restricted_user_access_key, null as restricted_user_access_type, CASE j.track WHEN 0 THEN false ELSE true END as tracksAccessByVolume,"issue" as access_level,j.issue_id,"" as article_id from `user_access_issue_trail` as `j` inner join `user_access_info` as `info` on `j`.`user_access_id` = `info`.`user_access_id` where ((j.from_ip <= 314383442 and j.to_ip >=314383442 )) and ((j.from_date <= 1739971901 and j.to_date >= 1739971901 and j.perpetual= 0) or (j.from_date is null and j.to_date is null and j.perpetual= 1)) and j.issue_id = 9455) union (select j.user_access_id,j.volume_id,j.user_id,j.from_ip,j.to_ip,j.type,j.track,"Subscribed" as access_base_text, false as terms_popup, "S" as content_download_type, null as restricted_user_access_key, null as restricted_user_access_type, CASE j.track WHEN 0 THEN false ELSE true END as tracksAccessByVolume,"issue" as access_level,j.issue_id,"" as article_id from `user_access_issue_corporate` as `j` inner join `user_access_info` as `info` on `j`.`user_access_id` = `info`.`user_access_id` where ((j.from_ip <= 314383442 and j.to_ip >=314383442 )) and ((j.from_date <= 1739971901 and j.to_date >= 1739971901 and j.perpetual= 0) or (j.from_date is null and j.to_date is null and j.perpetual= 1)) and j.issue_id = 9455) union (select j.user_access_id,j.volume_id,j.user_id,j.from_ip,j.to_ip,j.type,j.track,"Token Based Access" as access_base_text, false as terms_popup, "R" as content_download_type, j.uc_id as restricted_user_access_key, "v" as restricted_user_access_type, CASE j.track WHEN 0 THEN false ELSE true END as tracksAccessByVolume,"issue" as access_level,j.issue_id,"" as article_id from `user_access_issue_token` as `j` inner join `user_access_info` as `info` on `j`.`user_access_id` = `info`.`user_access_id` where ((j.from_ip <= 314383442 and j.to_ip >=314383442 )) and ((j.from_date <= 1739971901 and j.to_date >= 1739971901 and j.perpetual= 0) or (j.from_date is null and j.to_date is null and j.perpetual= 1)) and j.issue_id = 9455)
      920μsalphaeurekaselec_live_10_06_2022UserAccess.php#1266
      Backtrace
      • 13. app/Models/UserAccess/UserAccess.php:1266
      • 14. app/Http/Controllers/ArticleController.php:2297
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • (select j.user_access_id,j.volume_id,j.user_id,j.from_ip,j.to_ip,j.type,j.track,"Trial Access" as access_base_text, CASE j.type WHEN 111 THEN true ELSE false END as terms_popup, "S" as content_download_type, null as restricted_user_access_key, null as restricted_user_access_type, CASE j.track WHEN 0 THEN false ELSE true END as tracksAccessByVolume,"article" as access_level, j.issue_id, j.article_id from `user_access_article_trail` as `j` inner join `user_access_info` as `info` on `j`.`user_access_id` = `info`.`user_access_id` where ((j.from_ip <= 314383442 and j.to_ip >=314383442 )) and ((j.from_date <= 1739971901 and j.to_date >= 1739971901 and j.perpetual= 0) or (j.from_date is null and j.to_date is null and j.perpetual= 1)) and j.article_id = 93022) union (select j.user_access_id,j.volume_id,j.user_id,j.from_ip,j.to_ip,j.type,j.track,"Subscribed" as access_base_text, false as terms_popup, "S" as content_download_type, null as restricted_user_access_key, null as restricted_user_access_type, CASE j.track WHEN 0 THEN false ELSE true END as tracksAccessByVolume,"article" as access_level, j.issue_id, j.article_id from `user_access_article_corporate` as `j` inner join `user_access_info` as `info` on `j`.`user_access_id` = `info`.`user_access_id` where ((j.from_ip <= 314383442 and j.to_ip >=314383442 )) and ((j.from_date <= 1739971901 and j.to_date >= 1739971901 and j.perpetual= 0) or (j.from_date is null and j.to_date is null and j.perpetual= 1)) and j.article_id = 93022) union (select j.user_access_id,j.volume_id,j.user_id,j.from_ip,j.to_ip,j.type,j.track,"Token Based Access" as access_base_text, false as terms_popup, "R" as content_download_type, j.uc_id as restricted_user_access_key, "v" as restricted_user_access_type, CASE j.track WHEN 0 THEN false ELSE true END as tracksAccessByVolume,"article" as access_level, j.issue_id, j.article_id from `user_access_article_token` as `j` inner join `user_access_info` as `info` on `j`.`user_access_id` = `info`.`user_access_id` where ((j.from_ip <= 314383442 and j.to_ip >=314383442 )) and ((j.from_date <= 1739971901 and j.to_date >= 1739971901 and j.perpetual= 0) or (j.from_date is null and j.to_date is null and j.perpetual= 1)) and j.article_id = 93022)
      950μsalphaeurekaselec_live_10_06_2022UserAccess.php#1266
      Backtrace
      • 13. app/Models/UserAccess/UserAccess.php:1266
      • 14. app/Http/Controllers/ArticleController.php:2329
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select * from `article` where `first_page` < '6053' and is_uploaded = 1 and issue_id = 9455 order by cast(first_page as SIGNED) desc limit 1
      730μsalphaeurekaselec_live_10_06_2022Article.php#1819
      Bindings
      • 0: 6053
      Backtrace
      • 14. app/Models/Article.php:1819
      • 15. app/Http/Controllers/ArticleController.php:2470
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 17. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 18. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select * from `article` where `last_page` > '6073' and is_uploaded = 1 and issue_id = 9455 order by cast(first_page as SIGNED) asc limit 1
      660μsalphaeurekaselec_live_10_06_2022Article.php#1831
      Bindings
      • 0: 6073
      Backtrace
      • 14. app/Models/Article.php:1831
      • 15. app/Http/Controllers/ArticleController.php:2472
      • 16. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 17. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 18. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select `language_id` from `multilanguage` where `short_code` = 'en'
      250μsalphaeurekaselec_live_10_06_2022ArticleController.php#2497
      Bindings
      • 0: en
      Backtrace
      • 14. app/Http/Controllers/ArticleController.php:2497
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
      • 18. vendor/laravel/framework/src/Illuminate/Routing/Route.php:206
    • select `source_lang_label`, `target_lang_label` from `multilanguage_labels` where `target_lang_id` = 1
      310μsalphaeurekaselec_live_10_06_2022MultiLanguage.php#23
      Bindings
      • 0: 1
      Backtrace
      • 13. app/Models/MultiLanguage.php:23
      • 14. app/Http/Controllers/ArticleController.php:2498
      • 15. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 16. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
    • select `id` from `multilanguage_article` where `article_id` = 93022 limit 1
      2.97msalphaeurekaselec_live_10_06_2022ArticleController.php#2506
      Bindings
      • 0: 93022
      Backtrace
      • 16. app/Http/Controllers/ArticleController.php:2506
      • 17. vendor/laravel/framework/src/Illuminate/Routing/Controller.php:54
      • 18. vendor/laravel/framework/src/Illuminate/Routing/ControllerDispatcher.php:43
      • 19. vendor/laravel/framework/src/Illuminate/Routing/Route.php:260
      • 20. vendor/laravel/framework/src/Illuminate/Routing/Route.php:206
    • select b.banner_link, b.banner_name, b.banner_script, b.banner_remarks, b.banner_file_name, b.banner_placement, bd.content_type, bd.content_id from `tbl_banner` as `b` inner join `tbl_banner_detail` as `bd` on `bd`.`banner_id` = `b`.`banner_id` inner join `users` as `u` on `u`.`id` = `b`.`updated_by` inner join `journal` as `j` on `j`.`journal_id` = `bd`.`content_id` where `b`.`banner_journal` = 1 and `bd`.`content_type` = 'J' and `bd`.`content_id` = 25 and `b`.`banner_from_date` <= 1739971901 and `b`.`banner_to_date` >= 1739971901 and `b`.`banner_status` = 'A' order by `b`.`banner_id` desc
      1.72msalphaeurekaselec_live_10_06_2022Banner.php#95
      Bindings
      • 0: 1
      • 1: J
      • 2: 25
      • 3: 1739971901
      • 4: 1739971901
      • 5: A
      Backtrace
      • 13. app/Models/Banner.php:95
      • 14. app/Http/helpers.php:404
      • 17. vendor/laravel/framework/src/Illuminate/Filesystem/Filesystem.php:124
      • 18. vendor/laravel/framework/src/Illuminate/View/Engines/PhpEngine.php:58
      • 19. vendor/laravel/framework/src/Illuminate/View/Engines/CompilerEngine.php:73
    • select b.banner_link, b.banner_name, b.banner_script, b.banner_remarks, b.banner_file_name, b.banner_placement, bd.content_type, bd.content_id from `tbl_banner` as `b` inner join `tbl_banner_detail` as `bd` on `bd`.`banner_id` = `b`.`banner_id` inner join `users` as `u` on `u`.`id` = `b`.`updated_by` inner join `journal` as `j` on `j`.`journal_id` = `bd`.`content_id` where `b`.`banner_journal` = 1 and `bd`.`content_type` = 'J' and `bd`.`content_id` = 25 and `b`.`banner_from_date` <= 1739971901 and `b`.`banner_to_date` >= 1739971901 and `b`.`banner_status` = 'A' order by `b`.`banner_id` desc
      1.68msalphaeurekaselec_live_10_06_2022Banner.php#95
      Bindings
      • 0: 1
      • 1: J
      • 2: 25
      • 3: 1739971901
      • 4: 1739971901
      • 5: A
      Backtrace
      • 13. app/Models/Banner.php:95
      • 14. app/Http/helpers.php:404
      • 17. vendor/laravel/framework/src/Illuminate/Filesystem/Filesystem.php:124
      • 18. vendor/laravel/framework/src/Illuminate/View/Engines/PhpEngine.php:58
      • 19. vendor/laravel/framework/src/Illuminate/View/Engines/CompilerEngine.php:73
    • select count(*) as aggregate from `uc_cart_products` where cart_id='35b120098b0a8de28bd4ba524eac530e'
      330μsalphaeurekaselec_live_10_06_2022Cart.php#271
      Backtrace
      • 15. app/Models/Cart.php:271
      • 16. view::layouts._header:260
      • 18. vendor/laravel/framework/src/Illuminate/Filesystem/Filesystem.php:124
      • 19. vendor/laravel/framework/src/Illuminate/View/Engines/PhpEngine.php:58
      • 20. vendor/laravel/framework/src/Illuminate/View/Engines/CompilerEngine.php:73
    App\Models\MultiLanguage
    1MultiLanguage.php#?
    App\Models\MultiLangArticle
    1MultiLangArticle.php#?
        _token
        WRoLz8nVCQRaXvFWuqk68OU5CmA46Ff1EwmT5ElQ
        uc_cart_id
        35b120098b0a8de28bd4ba524eac530e
        _previous
        array:1 [ "url" => "http://alpha.eurekaselect.com/article/93022" ]
        _flash
        array:2 [ "old" => [] "new" => [] ]
        PHPDEBUGBAR_STACK_DATA
        []
        path_info
        /article/93022
        status_code
        200
        
        status_text
        OK
        format
        html
        content_type
        text/html; charset=UTF-8
        request_query
        []
        
        request_request
        []
        
        request_headers
        0 of 0
        array:8 [ "accept-encoding" => array:1 [ 0 => "gzip, deflate" ] "accept" => array:1 [ 0 => "text/html,application/xhtml+xml,application/xml;q=0.9,image/avif,image/webp,image/apng,*/*;q=0.8,application/signed-exchange;v=b3;q=0.7" ] "user-agent" => array:1 [ 0 => "Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)" ] "upgrade-insecure-requests" => array:1 [ 0 => "1" ] "cache-control" => array:1 [ 0 => "no-cache" ] "pragma" => array:1 [ 0 => "no-cache" ] "connection" => array:1 [ 0 => "keep-alive" ] "host" => array:1 [ 0 => "alpha.eurekaselect.com" ] ]
        request_cookies
        []
        
        response_headers
        0 of 0
        array:5 [ "content-type" => array:1 [ 0 => "text/html; charset=UTF-8" ] "cache-control" => array:1 [ 0 => "no-cache, private" ] "date" => array:1 [ 0 => "Wed, 19 Feb 2025 13:31:41 GMT" ] "set-cookie" => array:2 [ 0 => "XSRF-TOKEN=eyJpdiI6IjZzVHRyR1F6LzQwT2xEc20vck5ZZHc9PSIsInZhbHVlIjoiZmJsOXBoYldYWjE0ekZidkJZcHRPaUM0dWk5U1RJWm5La0orTG4yeklpYmFKRmxHSHJ0T1crQ3M5Q2VuZ1lmcS80cjhuUkJjNDAxd3dQb0ZicENJcklZOCtUWGQveGNhT1ppU3NXSHZ5eDNteFhoT2N5V2tGc0Q5NU1ObXUxcTIiLCJtYWMiOiI4MmFkYzM0NDk0ZGNmMTg1YzhlOTMzZjE1ZDM0ODhkMWY4YmMzOTM1NzNjMDdhMWU2OWRiZmRmYTQyZDg1M2ZiIiwidGFnIjoiIn0%3D; expires=Sat, 22 Feb 2025 01:31:41 GMT; Max-Age=216000; path=/; secure; samesite=laxXSRF-TOKEN=eyJpdiI6IjZzVHRyR1F6LzQwT2xEc20vck5ZZHc9PSIsInZhbHVlIjoiZmJsOXBoYldYWjE0ekZidkJZcHRPaUM0dWk5U1RJWm5La0orTG4yeklpYmFKRmxHSHJ0T1crQ3M5Q2VuZ1lmcS80cjhuU" 1 => "alphaeurekaselectnet_session=eyJpdiI6Iis2TlNWZWhYdGNLR3N3ZDJ3M01SK0E9PSIsInZhbHVlIjoiZ29PQzZTNHJmVW1RUS9pNjBXaGN5SVQ5eVRoUFNJME1mNnBVOVloSm0yNlhaK1NZVktrOHR0RmozM2tHak1TL0RlZTljMHV3UG9RWGVpdTN0U3ZQd1pESVB5SmlLZk9mK3VKMGxTN3JSbCtkK0NPVXlXZGE5RGQzYTdld0VGZHkiLCJtYWMiOiJmMTExYjg5NzhmMjljYTI3MmQzOGQ2OWQ4M2MyODA0ZmRiYTIyY2FkNTI1MGE1YmU2MWUyMmUxOGIxZDgxNDlkIiwidGFnIjoiIn0%3D; path=/; secure; httponly; samesite=laxalphaeurekaselectnet_session=eyJpdiI6Iis2TlNWZWhYdGNLR3N3ZDJ3M01SK0E9PSIsInZhbHVlIjoiZ29PQzZTNHJmVW1RUS9pNjBXaGN5SVQ5eVRoUFNJME1mNnBVOVloSm0yNlhaK1NZVktrOHR0Rmo" ] "Set-Cookie" => array:2 [ 0 => "XSRF-TOKEN=eyJpdiI6IjZzVHRyR1F6LzQwT2xEc20vck5ZZHc9PSIsInZhbHVlIjoiZmJsOXBoYldYWjE0ekZidkJZcHRPaUM0dWk5U1RJWm5La0orTG4yeklpYmFKRmxHSHJ0T1crQ3M5Q2VuZ1lmcS80cjhuUkJjNDAxd3dQb0ZicENJcklZOCtUWGQveGNhT1ppU3NXSHZ5eDNteFhoT2N5V2tGc0Q5NU1ObXUxcTIiLCJtYWMiOiI4MmFkYzM0NDk0ZGNmMTg1YzhlOTMzZjE1ZDM0ODhkMWY4YmMzOTM1NzNjMDdhMWU2OWRiZmRmYTQyZDg1M2ZiIiwidGFnIjoiIn0%3D; expires=Sat, 22-Feb-2025 01:31:41 GMT; path=/; secureXSRF-TOKEN=eyJpdiI6IjZzVHRyR1F6LzQwT2xEc20vck5ZZHc9PSIsInZhbHVlIjoiZmJsOXBoYldYWjE0ekZidkJZcHRPaUM0dWk5U1RJWm5La0orTG4yeklpYmFKRmxHSHJ0T1crQ3M5Q2VuZ1lmcS80cjhuU" 1 => "alphaeurekaselectnet_session=eyJpdiI6Iis2TlNWZWhYdGNLR3N3ZDJ3M01SK0E9PSIsInZhbHVlIjoiZ29PQzZTNHJmVW1RUS9pNjBXaGN5SVQ5eVRoUFNJME1mNnBVOVloSm0yNlhaK1NZVktrOHR0RmozM2tHak1TL0RlZTljMHV3UG9RWGVpdTN0U3ZQd1pESVB5SmlLZk9mK3VKMGxTN3JSbCtkK0NPVXlXZGE5RGQzYTdld0VGZHkiLCJtYWMiOiJmMTExYjg5NzhmMjljYTI3MmQzOGQ2OWQ4M2MyODA0ZmRiYTIyY2FkNTI1MGE1YmU2MWUyMmUxOGIxZDgxNDlkIiwidGFnIjoiIn0%3D; path=/; secure; httponlyalphaeurekaselectnet_session=eyJpdiI6Iis2TlNWZWhYdGNLR3N3ZDJ3M01SK0E9PSIsInZhbHVlIjoiZ29PQzZTNHJmVW1RUS9pNjBXaGN5SVQ5eVRoUFNJME1mNnBVOVloSm0yNlhaK1NZVktrOHR0Rmo" ] ]
        session_attributes
        0 of 0
        array:5 [ "_token" => "WRoLz8nVCQRaXvFWuqk68OU5CmA46Ff1EwmT5ElQ" "uc_cart_id" => "35b120098b0a8de28bd4ba524eac530e" "_previous" => array:1 [ "url" => "http://alpha.eurekaselect.com/article/93022" ] "_flash" => array:2 [ "old" => [] "new" => [] ] "PHPDEBUGBAR_STACK_DATA" => [] ]
        ClearShow all
        Date ↕MethodURLData
        #12025-02-19 13:31:41GET/article/93022314372